Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes
- PMID: 7706819
- DOI: 10.1093/infdis/171.4.909
Characterization of canine humoral immune responses to outer surface protein subunit vaccines and to natural infection by Lyme disease spirochetes
Abstract
Canine antibody responses to Lyme disease subunit vaccines and to natural borrelial infection were investigated. Vaccines were formulated with QS21 and outer surface proteins A (OspA) and B (OspB) derived from Borrelia burgdorferi B31. Vaccines containing QS21 and the lipoproteins gave 4-fold higher IgG1 and 8-fold higher IgG2 antibody responses than without QS21. Antisera to lipidated OspA or OspB vaccines containing QS21 had high antiborrelial activity against isolates B31 and CA-2-87, similar to those with a vaccine containing both OspA and OspB. Only the combination vaccine induced antiborrelial activity against heterologous isolates 24008 Fr and Borrelia garinii G25. Nonlipidated OspA- and OspB-based vaccines with QS21 elicited lower antibody and antiborrelial activity than did lipidated OspA and OspB vaccines; 49% of naturally exposed dogs had low titers to OspA or OspB. Thus, vaccines using lipidated OspA, OspB, and QS21 could induce higher antiborrelial activity than did natural exposure.
Similar articles
-
Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi.Vaccine. 1994 Aug;12(10):925-32. doi: 10.1016/0264-410x(94)90036-1. Vaccine. 1994. PMID: 7975834
-
Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.J Infect Dis. 1995 Apr;171(4):1049-52. doi: 10.1093/infdis/171.4.1049. J Infect Dis. 1995. PMID: 7706788
-
Immune sera to individual Borrelia burgdorferi isolates or recombinant OspA thereof protect SCID mice against infection with homologous strains but only partially or not at all against those of different OspA/OspB genotype.Vaccine. 1993;11(10):1049-54. doi: 10.1016/0264-410x(93)90132-h. Vaccine. 1993. PMID: 8212826
-
A recombinant vaccine for Lyme disease.Behring Inst Mitt. 1994 Dec;(95):106-8. Behring Inst Mitt. 1994. PMID: 7755503 Review.
-
Functional heterogeneity in the antibodies produced to Borrelia burgdorferi.Wien Klin Wochenschr. 1999 Dec 10;111(22-23):985-9. Wien Klin Wochenschr. 1999. PMID: 10666815 Review.
Cited by
-
Vaccine delivery using nanoparticles.Front Cell Infect Microbiol. 2013 Mar 25;3:13. doi: 10.3389/fcimb.2013.00013. eCollection 2013. Front Cell Infect Microbiol. 2013. PMID: 23532930 Free PMC article. Review.
-
Vaccines for canine leishmaniasis.Front Immunol. 2012 Apr 17;3:69. doi: 10.3389/fimmu.2012.00069. eCollection 2012. Front Immunol. 2012. PMID: 22566950 Free PMC article.
-
Antibodies against specific proteins of and immobilizing activity against three strains of Borrelia burgdorferi sensu lato can be found in symptomatic but not in infected asymptomatic dogs.J Clin Microbiol. 2000 Jul;38(7):2611-21. doi: 10.1128/JCM.38.7.2611-2621.2000. J Clin Microbiol. 2000. PMID: 10878052 Free PMC article.
-
Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.Drugs. 2000 Feb;59(2):281-99. doi: 10.2165/00003495-200059020-00019. Drugs. 2000. PMID: 10730551
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical